Searle & Co’s Oculis Holding OCS Stock Holding History

Searle & Co’s Portfolio OCS Stock Details OCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$11K	–	166
2023 Q4	$11K	Buy	+10,000	New	+$104K	﹤0.01%	159

Other funds holding OCS

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Searle & Co's OCS Position: Q1 2024 in Review

Searle & Co sold out of Oculis Holding (OCS) in Q1 2024, closing a stake of 10,000 shares — an estimated $11K sold.

Searle & Co first reported a position in OCS in Q4 2023 and held it in 1 quarter. The position peaked at $11K in Q4 2023. 9 funds tracked by Wall St. Rank hold OCS as of Q1 2024.

Searle & Co reported no remaining Oculis Holding position as of Q1 2024 after selling out during the quarter.
Searle & Co sold 10,000 Oculis Holding shares in Q1 2024, an estimated $11K.
Searle & Co first reported a position in Oculis Holding in Q4 2023 and held it in 1 quarter.
Searle & Co's Oculis Holding position peaked at $11K in Q4 2023.
9 funds tracked by Wall St. Rank held Oculis Holding as of Q1 2024.

Based on Searle & Co's 13F filing for Q1 2024, filed 9 May 2024.